Behavioral Pharmacology of Anxiolytics
Anxiety is a term applied by clinicians to certain manifestations in patients. Clinical anxiety has three components. First there is a verbal component: The patient says that he or she is anxious or fearful or gives a semantically similar description. Second, there is a somatic-autonomic component. The patient is restless and agitated, has a higher heart rate, and sweats. Third, there is an interference with normal productive activities. Clinical anxiety should probably not be diagnosed if any of these three components is entirely lacking. In the clinical assessment of anxiety by history and physical examination, all three components are taken into account.
KeywordsAgonistic Behavior Minnesota Multiphasic Personality Inventory Clinical Anxiety Behavioral Pharmacology Anxiolytic Agent
Unable to display preview. Download preview PDF.
- Allen, J.A., Mewha, L.S., Roddie, I.C.: The effect of diazepam on performance and emotional response during viva examination. J. Physiol. (Lond.) 263, 191P–192P (1976)Google Scholar
- Barlow O.W.: The tranquilizing potency of morphine, pantopan, codeine, papaverine and narcotine. J. Am. Med. Ass. 99, 986–988 (1932)Google Scholar
- Berger, F.M., Bradley, W.: The pharmacological properties of α:β-dihydroxy-α-(2-methyl- phenoxy) propane (Myanesin). Br. J. Pharmacol. 1, 265–272 (1946)Google Scholar
- Dews, P.B.: Effects of drugs on suppressed responding. Br. J. Pharmacol. 58, 451 P (1976)Google Scholar
- Dews, P.B., DeWeese, J.: Schedules of reinforcement. In Handbook of Psychopharmacology. Iversen, L.L., Iversen, S.D., Snyder, S.H. (eds.), Vol. 7, pp. 107–150. New York: Plenum Press 1977Google Scholar
- Henneman, E., Kaplan, A., Unna, K.: A neuropharmacological study on the effect of myanesin (Tolserol) on motor systems. J. Pharmacol. 97, 331–341 (1949)Google Scholar
- Hoff meister, F., Wuttke, W.: On the actions of psychotropic drugs on the attack — and aggressive — defensive behavior of mice and cats. In Aggressive behavior. Garattini, S., Sigg, E.B. (eds.), pp. 273–280. New York: Wiley 1969Google Scholar
- Kelleher, R.T., Fry, W., Deegan, J., Cook, L.: Effects of meprobamate on operant behavior in rats. J. Pharmacol. 133, 271–280 (1961)Google Scholar
- Miczek, K.A., Krsiak, M.: Drug effects on agonistic behavior. In Advances in behavioral pharmacology. Thompson, T., Dews, P.B. (eds.), Vol. 2, pp. 88–153. New York: Academic Press 1979Google Scholar
- Rickels, K., Downing, R.W., Winokur, A.: Antianxiety drugs: Clinical use in psychiatry. In Handbook of Psychopharmacology. Iversen, L.L., Iversen, S.D., Snyder, S.H. (eds.), Vol. 13, pp. 395–430. New York: Plenum 1978Google Scholar
- Sepinwall, J., Cook, L.: Behavioral pharmacology of antianxiety drugs. In Handbook of Psychopharmacology. Iversen, L.L., Iversen, S.D., Snyder, S.H. (eds.), Vol. 13, pp. 345–385. New York: Plenum 1978Google Scholar